Theravance Biopharma, Inc. SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense
Theravance Biopharma, Inc. (TBPH) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense of $7.63 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-27.
Discontinued › Notes › Valuation and Qualifying Accounts
us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense · last filed 2020-02-27
- Theravance Biopharma, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2018-12-31 was $1.43M.
- Theravance Biopharma, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2018-09-30 was $1.99M.
- Theravance Biopharma, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2018-06-30 was $2.48M.
- Theravance Biopharma, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2018-03-31 was $1.74M.
- Theravance Biopharma, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2018 was $7.63M, a 20.19% increase from fiscal 2017.
- Theravance Biopharma, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2017 was $6.35M.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 3 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 6 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 9 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month |
|---|---|---|---|---|
| 2018-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $3.41M derived: sum of 2 quarters · filed 2020-02-27 | $5.89M derived: sum of 3 quarters · filed 2020-02-27 | $7.63M 10-K · filed 2020-02-27 |
| 2018-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $4.47M derived: sum of 2 quarters · filed 2018-11-08 | $6.20M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $4.21M 10-Q · filed 2018-08-02 | ||
| 2018-03-31 | $1.74M 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | $6.35M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |